Venture capitalist named as UMass Medical vice chancellor
File photo
A new rabies vaccine developed by UMass Medical School should reduce prevention gaps in India.
Prominent venture capitalist Jim Glasheen will join UMass Medical School on Dec. 4 as the executive vice chancellor for innovation and business development.
Glasheen, who spent 15 years as a general partner in the venture capital fund Technology Partners in California, will take over for founding Executive Vice Chancellor Brendan O’Leary, who the school said has “led a comprehensive approach to business development, innovation and advancing industry partnerships.”
Glasheen was an investor or board member in several companies, including, Cadence Pharmaceuticals (acquired by Mallinckrodt), Revance Therapeutics, Iomai (acquired by Intercell), Incline Therapeutics (acquired by the Medicines Company), Transcend Medical (acquired by Novartis), Vision 5 (acquired by Allergan), Corcept and Elcelyx.
Glasheen, a Harvard and Duke graduate with a Ph.D. in biology, is the co-founder and co-chairman of ConsumerMed, a nonprofit organization focused on patient-centered health.
Before his venture career, Glasheen was a consultant with management consulting firm McKinsey and Co.
WBJ Web Partners
Most Recent
Most Recent
0 Comments